[DEBUG-WINDOW 처리영역 보기]
즐겨찾기  |  뉴스레터  |  오늘의 정보  |  e브릭몰e브릭몰 회원가입   로그인
BRIC홈 한국을 빛내는 사람들
스폰서배너광고 안내  배너1 배너2 배너3 배너4
전체보기 추천논문 상위피인용논문 인터뷰 그이후 한빛사통계
이종욱 (Jong Wook Lee) 저자 이메일 보기
가톨릭대학교 의과대학, 서울성모병원
조회 224  인쇄하기 주소복사 트위터 공유 페이스북 공유 
Romiplostim in patients with refractory aplastic anaemia previously treated with immunosuppressive therapy: a dose-finding and long-term treatment phase 2 trial
열기 Authors and Affiliations


Aplastic anaemia is a rare, life-threatening condition, characterised by pancytopenia with hypocellular bone marrow. Haematopoietic stem cells and most progenitor cells express thrombopoietin receptor (c-MPL). Romiplostim is a peptibody with c-MPL agonist activity that stimulates endogenous thrombopoietin production and leads to promoting the proliferation and differentiation of megakaryocytes in the bone marrow. In this phase 2 trial we aimed to assess the activity and safety of romiplostim in patients with aplastic anaemia who were previously treated with immunosuppressive therapy.

We did an open-label, phase 2 study including a randomised, parallel, dose-finding part followed by an extension part to evaluate long-term treatment at two clinical centres in Seoul, South Korea. Eligible patients were aged 19 years or older, and had aplastic anaemia confirmed by bone marrow and cytogenetic studies and thrombocytopenia (platelet count ≤30 × 109/L), an Eastern Cooperative Oncology Group performance status score of 2 or lower, and were previously treated with immunosuppressive therapy, including at least one course of antithymocyte globulin plus cyclosporin. In the dose-finding part, patients were randomly assigned to fixed dose cohorts (1, 3, 6, or 10 μg/kg) of subcutaneous romiplostim once weekly for 8 weeks, according to a static allocation procedure after stratification by platelet count. In the extension part of the study, patients continued romiplostim titrated every 4 weeks in single steps (1, 3, 6, 10, 13, 16, and 20 μg/kg once weekly), depending on platelet response and safety up to 1 year (weeks 9–52). Patients who had a platelet response during weeks 46–53 continued dose titration in single steps (3, 6, 10, 13, 16, and 20 μg/kg once weekly) for an additional 2 years (weeks 53–156). The primary endpoint was the proportion of patients achieving a platelet response at week 9 (after completion of the dose-finding part). Activity was assessed per-protocol in all patients evaluable for response at week 9 and safety was assessed in all patients who received at least one dose of romiplostim. This trial is registered with ClinicalTrials.gov, NCT02094417.

Between April 14 and Nov 24, 2014, 35 patients were enrolled and randomly assigned to one of four dose cohorts: romiplostim 1 μg/kg (n=7), 3 μg/kg (n=9), 6 μg/kg (n=9), and 10 μg/kg (n=10). Data cutoff for this final analysis was on April 14, 2018. The median duration of treatment for all patients was 53 weeks (IQR 35–155). Ten (30%) of 33 evaluable patients achieved a platelet response at week 9, including seven (70%) of ten patients in the 10 μg/kg cohort, three (33%) of nine patients in the 6 μg/kg cohort, and no patients in both the 3 μg/kg and 1 μg/kg cohorts. During the extension study, 18 (55%) of 33 evaluable patients had a platelet response during weeks 46–53 and were eligible for continued treatment. Ten (30%) patients maintained a platelet response at 2 and 3 years, of whom nine had an erythroid response and five a neutrophil response, and completed protocol treatment. Treatment-related adverse events occurred in three (9%) of 35 patients, including grade 1 or 2 myalgia, fatigue, and dizziness. 17 (49%) of 35 patients had adverse events of grade 3 or higher; seven (20%) had serious adverse events (one event of febrile neutropenia, cataract, retinal detachment, macular fibrosis, inguinal hernia, appendicitis, cellulitis, tendon injury, and transfusion reaction); and one patient died from sepsis during treatment; none of these events were related to treatment. No patients developed clonal evolution.

Romiplostim seems to be active and has a favourable safety profile in patients with refractory aplastic anaemia. 10 μg/kg once weekly might be used as a recommended starting dose in future studies. These findings warrant further investigation.

Kyowa Hakko Kirin Korea.

- 형식: Research article
- 게재일: 2019년 08월 (BRIC 등록일 2019-09-02)
- 연구진: 국내(교신)+국외 연구진태극기
- 분야: Medicine
TLR3 활성화에 의해 유도된 레티노익산 합성이 모낭 재생에 미치는 영향[Nat. Commun.]
발표: 김동원 (Dongseo University)
일자: 2019년 9월 27일 (금) 오전 10시 (한국시간)
참석자 접수신청하기

  댓글 0
Springer Nature
이종욱 님 전체논문보기 >
장준호 (성균관대학교 의과대학, 삼성...)
관련분야 논문보기

Google (by Jong Wook Lee)
Pubmed (by Jong Wook Lee)
프리미엄 Bio일정 Bio일정 프리미엄 안내
10월의 하늘에서 도서관 과학 강연을 해주실 강연기부 신청을 받고 있습니다.
「국가연구개발 혁신을 위한 특별법」 대토론회
「국가연구개발 혁신을 위한 특별법」 대토론회
날짜: 2019.09.23
장소: 과학기술단체총연합회 지하 1층 대강당(서울 강남구)
뇌과학원천기술개발사업 신개념 치매 원인 규명을 위한 한국형 국가 R&D 플랫폼 구축 사업단 국제 심포지움
뇌과학원천기술개발사업 신개념 치매 원인 규명을 위한 한국형 국가 R&D 플랫폼 구축 사업단 국제 심포지움
날짜: 2019.10.04
장소: 대구경북과학기술원 (대구광역시 달성군 현풍읍 테크노중앙대로 333)
[BRIC Webinar]TLR3 활성화에 의해 유도된 레티노익산 합성이 모낭 재생에 미치는 영향[Nat. Commun.]
2019년도 제 25차 대한의생명과학회 추계학술대회
2019년도 제 25차 대한의생명과학회 추계학술대회
초록접수: ~2019.10.08
사전접수: ~2019.10.08
날짜: 2019.10.25~26
장소: 대구 EXCO 211호 국제회의실
한빛사 홈  |  한빛사FAQ  |  한빛사 문의 및 제안
 |  BRIC소개  |  이용안내  |  이용약관  |  개인정보처리방침  |  이메일무단수집거부
Copyright © BRIC. All rights reserved.  |  문의 member@ibric.org
트위터 트위터    페이스북 페이스북   유튜브 유튜브    RSS서비스 RSS